Therapeutic Response

EGFR Exon 19 (Deletion) status confers therapeutic sensitivity to Dacomitinib in patients with Non-Small Cell Lung Cancer.

Statements

Source and description
Vizimpro (dacomitinib) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to dacomitinib for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations, as detected by an FDA-approved test.